Overexpression of enolase 1 (ENO1), another glycolytic enzyme, in HCC, especially in metastatic lesions, can often indicate worse clinical characterizations including tumor-node-metastasis (TNM) stage, differentiation grade, and poorer prognosis (Jiang et al., 2020). This evidence concerns the gene ENO1 and neoplasm.